| Literature DB >> 32023809 |
Nicole M Sekel1, Sina Gallo1,2, Jennifer Fields2,3, Andrew R Jagim4, Tammy Wagner1, Margaret T Jones2,3.
Abstract
Vitamin D may play a role in performance and injury risk, yet the required supplementation dosage for collegiate athletes is unclear. The objective of this study was to define the dosage of vitamin D3 supplementation required to beneficially affect serum 25-hydroxyvitamin D (25(OH)D) among a sample of collegiate basketball athletes. This was a quasi-experimental trial, participants were allocated to one of three groups of vitamin D3 daily at the beginning of pre-season training and dependent upon their baseline vitamin D status as follows: insufficient (<75 nmol/L) to 10,000 IU, sufficient (75-125 nmol/L) to 5000 IU and optimal (>125 nmol/L) to no supplementation. Follow-up assessments were completed ~ 5 months later in post season. The majority (n = 13) were allocated to 10,000 IU vs. n = 5 to 5000 IU and n = 2 to no supplementation. The 10,000 IU group showed the greatest change (35.0 ± 27.0 nmol/L) vs. the 5000 IU group (-9.3 ± 9.6 nmol/L) and no supplementation group (-41.6 ± 11.7 nmol/L, p < 0.01). Only 1 participant reached optimal status in the 10,000 IU group. In conclusion, a daily dosage of 10,000 IU vitamin D3 supplementation mitigated the high prevalence of vitamin D deficiency among collegiate basketball players but was insufficient for all to reach sufficient levels.Entities:
Keywords: 25-hydroxyvitamin D; basketball; collegiate athletes; skin pigmentation; supplementation; vitamin D
Mesh:
Substances:
Year: 2020 PMID: 32023809 PMCID: PMC7071343 DOI: 10.3390/nu12020370
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Vitamin D supplementation regimens.
| Vitamin D Status Definition | Baseline 25(OH)D Concentration | Supplementation Regimen (IU/d) 1 |
|---|---|---|
| Insufficient | <75nmol/L (30 ng/mL) | 10,000 IU/cap/day |
| Sufficient | 75–125 nmol/L (30–50 ng/mL) | 5000 IU/cap/day |
| Optimal | >125 nmol/L (50 ng/mL) | No Supplementation |
1 Treatment dosages based on clinical practice guidelines in conjunction with a Registered Dietitian [18,19,20].
Baseline characteristics of participants by intervention groups. Presented as mean ± SD for continuous variables and n (%) for categorical variables.
| Variable | Overall | Intervention Groups | |||
|---|---|---|---|---|---|
| No Supplement | 5000 IU/day | 10,000 IU/day | |||
| Serum 25(OH)D (nmol/mL) | 75.56 ± 31.95 | 153.38 ± 23.16 a | 89.4 ± 15.89 a | 58.27 ± 8.62 a | <0.001 |
| Age (years) | 20.25 ± 0.9 | 21 ± 0.0 | 20.6 ± 0.9 | 20 ± 0.8 | 0.175 |
|
| |||||
| Male | 10 (50%) | 0 (0%) | 0 (0%) | 10 (76.9%) | 0.005 |
| Female | 10 (50%) | 2 (20%) | 5 (50%) | 3 (30%) | |
|
| |||||
| White/Anglo | 6 (30.0%) | 2 (100%) | 2 (40%) | 2 (15.4%) | 0.027 |
| African American | 12 (60%) | 0 (0%) | 1 (20%) | 11 (84.6%) | |
| Latino | 1 (5%) | 0 (0%) | 1 (20%) | 0 (0%) | |
| Mixed | 1 (5%) | 0 (0%) | 1 (20%) | 0 (0%) | |
|
| |||||
| Dark or olive (≤10–28°) | 12 (70.6%) | 0 (0%) | 2 (50%) | 10 (90.9%) | 0.022 |
| Medium (28–41°) | 4 (23.5%) | 2 (100%) | 1 (25%) | 1 (9.1%) | |
| Fair or very fair (41°<) | 1 (5.9%) | 0 (0%) | 1 (25%) | 0 (0%) | |
|
| |||||
| Whole body BMD (g/cm) | 1.28 ± 0.1 | 1.21 ± 0.0 | 1.26 ± 0.0 | 1.3 ± 0.1 | 0.447 |
| Whole body BMD Z-Score | 1.1 ± 0.8 | 1.6 ± 0.0 a | 1.78 ± 0.7 a,b | 0.76 ± 0.7 a,c | 0.029 |
| Fat Mass (kg) | 16.45± 8.2 | 16.62 ± 6.5 | 18.23± 4.5 | 15.73± 9.7 | 0.859 |
| Lean Mass (kg) | 63.82± 11.3 | 54.25 ± 4.9 a | 53.1 ± 5.2 a,b | 69.44± 9.6 a,c | 0.004 |
| Lean mass (kg)/total mass (kg) × 100 (%) | 76.8 ± 6.7 | 74.04 ± 4.9 | 71.88 ± 3.0 | 79.12 ± 7.0 | 0.094 |
| Body Fat (%) | 19.45 ± 7.1 | 22.2 ± 5.3 | 24.4 ± 3.3 | 17.13 ± 7.5 | 0.124 |
|
| |||||
| Vitamin D, total (IU/day) | 350.02 ± 333.0 | 367.07 ± 211.4 | 359.41 ± 304.1 | 343.78 ± 375.3 | 0.994 |
|
| |||||
| Time spent outdoors (weekday), <40 min. | 17 (85%) | 2 (100%) | 4 (80%) | 11 (84.6%) | 0.798 |
| Time spent outdoors (weekend), <40 min. | 12 (60%) | 1 (50%) | 1 (20%) | 10 (76.9%) | 0.083 |
| Average minutes/day of direct sunlight exposure, <30 min. | 15 (75%) | 1 (50%) | 4 (80%) | 10 (76.9%) | 0.684 |
1 Participants allocated to group at baseline if fell within optimal range (>125 nmol/L); 2 Participants allocated to group at baseline if fell within sufficient range (75–125 nmol/L); 3 Participants allocated to group at baseline if fell within insufficient range (<75 nmol/L); 4 Based on dual-energy x-ray absorptiometry (DXA); 5 Based on Nutrition Data Systems for Research (NDSR) data at follow-up; 6 Self-reported at baseline; 7 A one-way analysis of variance (ANOVA) or chi square (X2) test were used to assess mean differences in characteristics across intervention groups; 8 Different letter superscripts identify significant differences among groups as per post-hoc testing; 9 p value of ≤0.05 determines statistical significance.
25(OH)D status at follow-up by intervention dosage. Presented as n (%).
| Status at Follow-Up | Status at Baseline | |||
|---|---|---|---|---|
| No Supplement | 5000 IU/day | 10,000 IU/day | ||
| Insufficient < 75 nmol/L | 0 (0%) | 1 (25%) | 3 (23.1%) | 0.395 |
| Sufficient 75–125 nmol/L | 1 (50%) | 3 (75%) | 9 (69.2%) | |
| Optimal > 125 nmol/L | 1 (50%) | 0 (0%) | 1 (7.7%) | |
1 Total of 5 participants were allocated to 5000 IU D3 at baseline but only 4 remained at follow-up due attrition; 2 Chi square (X2) test were used to assess differences in vitamin D status at follow-up across intervention groups; 3 p value of ≤0.05 determines statistical significance.
Figure 1Change of 25(OH)D concentrations (nmol/L) by intervention group.
Figure 225(OH)D concentrations at baseline and follow-up by group and individual.